Skip to content
Sunday 16 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,750.11
-0.21%
DAX
26,440.31
+0.53%
CAC 40
8,636.80
-0.16%
STOXX 50
6,539.59
-0.09%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Thursday 03 June 2021 3:53 pm  |  Updated:  Thursday 03 June 2021 5:55 pm

More than half of UK adults have now received two vaccine doses

By: Hannah Godfrey

Add as a preferred source on Google
Vaccine Centre Opens To Accommodate Over-Forties In Cohort 10
It follows yesterday's news that three-quarters of adults have received their first jab. (Photo by Ian Forsyth/Getty Images)

More than half of all adults in the UK have now received two doses of the Covid vaccine as the rollout continues with pace.

The milestone follows yesterday’s news that more than three-quarters of adults have had their first jab.

“Over half of UK adults have now been fully vaccinated and have maximum protection against this awful virus, which is heart-warming news,” said vaccines minister Nadhim Zahawi.

“Everyone who has received their second dose can breathe a huge sigh of relief knowing that they have ultimate protection from the virus and the new variants.”

Another Important milestone today. 50% of all adults in the U.K. have had the protection of two doses. Thank you to a brilliant team. We keep going. @Emily_JR_Lawson @maddymcternan @jonathanleach13 @NikkiKF @AHamiedNHS @NHSuk 💉💉💉

— Nadhim Zahawi (@nadhimzahawi) June 3, 2021

Health services across the UK have now administered more than 66.1m jabs between 8 December and 2 June.

The government says it is on track to offer a first dose to all adults by the end of July.

“We know how important the second dose is to give protection, particularly against the Delta variant,” said health secretary Matt Hancock.

“Let’s roll up our sleeves and put this pandemic behind us, once and for all.”

Read more

Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

‘India variant’ now dominant in UK

Public Health England (PHE) today confirmed the variant first found in India is now the dominant variant in the UK.

Cases of the India variant have risen by 5,472 since last week to 12,431.

According to PHE, early evidence suggests the there may be an increased risk of hospitalisation associated with the variant, although the health body said it needs more evidence to know for sure.

This week, 278 people with the variant attended A&E, resulting in 94 people being admitted to hospital overnight.

Last week, 201 people attended A&E, with 43 admissions. The majority of those had not been vaccinated.

Dr Jenny Harries, chief executive of the UK Health Security Agency, said: “With this variant now dominant across the UK, it remains vital that we all continue to exercise as much caution as possible.

“The way to tackle variants is to tackle the transmission of Covid-19 as a whole. Work from home where you can, and practice ‘hands, face, space, fresh air’ at all times.”

Read more

VoxNeuro Receives FDA 510(k) Clearance for Cognitive Function Neuroimaging (cfNI) Software – An Objective EEG/ERP Brain Health Assessment

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Coronavirus
  • Vaccine

Trending Articles

  • Grandparents fund university degrees to avoid inheritance tax net

  • Revolut chatbot goes rogue by charging users to cancel subscription

  • Brompton Bicycle sues former adviser for ‘professional negligence’

  • Revolut takes flight with launch of new airport lounges

  • Is the Zeekr 9X Super Hybrid the new luxury SUV to beat?

More from Morning Wire

  • Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

    Business Wire
  • VoxNeuro Receives FDA 510(k) Clearance for Cognitive Function Neuroimaging (cfNI) Software – An Objective EEG/ERP Brain Health Assessment

    Business Wire
  • ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults; alongside INSTI-powered long-acting injectable innovation at AIDS 2026

    Business Wire
  • Tenpoint Therapeutics Announces United Kingdom Submission of Marketing Authorization Application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Blurry Close-Up Vision (Presbyopia) in Adults

    Business Wire
  • Andy Burnham’s technical education reforms are doomed to fail

    Opinion
    Andy Burnham, Mayor of Greater Manchester, in a high-vis vest at a technical education event.
  • People read less: Do we still need the Booker Prize?

    Life&Style
    Collection of eight Booker Prize-nominated book covers, featuring various authors and titles.
  • Screens aren’t the problem, it’s what’s on them that’s rotting our brains

    Opinion
    Unfortunately, without additional context from the article or details about what the image depicts, it is challenging to g...
  • Is ABBA Voyage suitable for children? You bet it is!

    Life&Style
    ABBA Voyage concert at ABBA Arena London with performers on stage and a large audience.
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook